Turning Heart Failure into Heart Success: Integrating Barostim into a Comprehensive Heart Failure Program

Despite the use of effective drug and device therapies, many patients with HFrEF continue to experience worsening symptoms and disease progression. Barostim is a novel device therapy that works with drug therapies to target the neurohormonal pathways responsible for heart failure progression and symptoms. Most importantly, 94% of patients receiving the device had significant improvement in quality of life, exercise capacity or functional status heart failure symptoms.(1)

Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Recall | Product recall

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.